Global Infectious Diseases Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Assays, Kits & Reagents, Instruments and Services & Software.

By Technology;

Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-Generation Sequencing, and DNA Microarray.

By Disease Type;

Hepatitis, Human Immunodeficiency Virus, Chlamydia Trachomatis Genital Infection and Gonorrhea, and Hospital-Acquired Infections.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn875335187 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Infectious Diseases Market (USD Million), 2021 - 2031

In the year 2024, the Global Infectious Diseases Market was valued at USD 62,715.97 million. The size of this market is expected to increase to USD 123,779.67 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.2%.

The infectious disease market, particularly concerning bacterial infections, is experiencing a notable upsurge in demand for rapid diagnostics and effective treatments, predominantly due to the escalation of antibiotic-resistant strains. This emergence of drug-resistant bacteria poses a significant global health threat, compelling the healthcare industry to seek innovative solutions to address this challenge. Companies such as Cepheid and Tetraphase Pharmaceuticals are at the forefront of capitalizing on this trend by spearheading the development of cutting-edge testing platforms and novel antibiotics, respectively.

Cepheid, renowned for its expertise in molecular diagnostics, is pioneering the development of innovative testing platforms aimed at providing rapid and accurate detection of bacterial pathogens. These platforms utilize advanced molecular techniques to identify antibiotic-resistant strains swiftly, enabling healthcare providers to make informed treatment decisions promptly. Simultaneously, Tetraphase Pharmaceuticals is focusing on the development of novel antibiotics that target multidrug-resistant bacteria. By leveraging innovative drug discovery approaches, Tetraphase aims to address the unmet medical need for effective treatments against resistant bacterial infections, thereby contributing to the global effort to combat antimicrobial resistance.

This surge in demand for advanced solutions to combat bacterial infections underscores the urgent need for investment and innovation in the infectious disease market. Companies are increasingly focusing on developing products and technologies that not only address current challenges but also anticipate future needs in the fight against antibiotic resistance. In addition to market insights such as market value, growth rate, segmentation, geographical coverage, and major players, comprehensive market reports provided by organizations like Data Bridge Market Research also offer in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework assessments. These detailed reports play a crucial role in guiding stakeholders in making informed decisions and navigating the complex landscape of infectious disease management.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Technology
    3. Market Snapshot, By Disease Type
    4. Market Snapshot, By Region
  4. Global Infectious Diseases Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increased demand for rapid diagnostic solutions
        2. Government initiatives
      2. Restraints
        1. High cost of diagnostics and treatments
        2. Stringent regulatory requirements
      3. Opportunities
        1. Focus on emerging markets
        2. Telemedicine and remote diagnostics
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Infectious Diseases Market, By Product, 2021 - 2031 (USD Million)
      1. Assays
      2. Kits & Reagents
      3. Instruments
      4. Services & Software
    2. Global Infectious Diseases Market, By Technology, 2021 - 2031 (USD Million)
      1. Immunodiagnostics
      2. Clinical Microbiology,
      3. Polymerase Chain Reaction
      4. Isothermal Nucleic Acid Amplification Technolog
      5. DNA Sequencing & Next-Generation Sequencing
      6. DNA Microarray,
    3. Global Infectious Diseases Market, By Disease Type, 2021 - 2031 (USD Million)
      1. Hepatitis
      2. Human Immunodeficiency Virus
      3. Chlamydia Trachomatis Genital Infection and Gonorrhe
      4. Hospital-Acquired Infections
    4. Global Infectious Diseases Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott Laboratories
      2. BD
      3. bioMérieux SA
      4. Bio-Rad Laboratories, Inc
      5. Danaher
      6. DiaSorin S.p.A
      7. Luminex Corporation
      8. Meridian Bioscience, Inc
      9. Quidel Corporation
      10. F. Hoffmann-La Roche Ltd,
      11. Siemens
      12. OraSure Technologies, Inc.
  7. Analyst Views
  8. Future Outlook of the Market